GIM1
(N-1) |
A phase III randomized study of Sequential Epidoxorubicin plus Cyclophospamide Followed By Docetaaxel (EC->D) versus the Combination of 5-fluorouracil, Epidoxorubicin and Cyclophospamide (FEC) as Adjuvant Treatment of Node-Negative Early Breast Cancer Patients. |
GIM2
|
A phase III randomized study of EC followed by Paclitaxel versus FEC followed by Paclitaxel, all given either every 3 or 2 weeks supported by Pegfilgrastim for node positive breast cancer patients. |
GIM3
(FATA) |
A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer. |
GIM4
(LEAD) |
LEtrozole Adjuvant therapy Duration (LEAD) study: standard versus long treatment. A phase III trial in post-menopausal women with early breast cancer. |
GIM5
(CYPLEC) |
Letrozole adjuvant therapy after Tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients. |
GIM6
(PROMISE) |
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with Triptorelin versus control in young breast cancer patients. A randomized phase III multicenter study. |
GIM7
(DOT) |
Dose Optimization of Trastuzumab. Studio di fase III volto a valutare l'efficacia e la tossicità di Trastuzumab alla dose di mantenimento di 1mg/kg/settimana verso la dose standard di 2mg/kg/settimana in combinazione con chemioterapia nelle pazienti con carcinoma mammario metastatico. |
GIM8
(OVER) |
A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy. |
GIM9
(NEO-ADIXERN) |
A feasibility study of dose-dense FEC with G-CSF support followed by dose-dense Ixabepilone with G-CSF support as neoadjuvant chemotherapy in ER-negative breast cancer. |
GIM10
(CONSENT) |
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrine-responsive early breast cancer. |
GIM11
(BERGI) |
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Progressing after First-Line Therapy With Bevacizumab and Paclitaxel. |
GIM12
(TYPHER) |
A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to anti HER2 therapies. |
GIM13
(AMBRA) |
Observation of Medical Treatments in MBC HER2-negative Patients (Advanced Metastatic BReAst Cancer). |
GIM14
(BIO-META) |
Evaluation of medical treatments (chemotherapy, hormonal therapy and biological therapies) in metastatic breast cancer patients according to biologic subtype and line of treatment. |
GIM15
(NEPA) |
One day antiemetic prophylaxis of NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving a combination chemotherapy of doxorubicin or epirubicin with cyclophosphamide (AC-based regimen). |
GIM16
(FEVEX) |
Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial. |
GIM18
(FUMANCE) |
Randomized phase III study of fulvestrant as maintenance therapy after first-line chemotherapy in HER2 negative postmenopausal metastatic breast cancer patients. |
GIM19
(STAR) |
Observational study on evaluation of compliance to aromatase inhibitors treatment in patients with hormone positive breast cancer. |
GIM20
(CITOHER2) |
A prospective, exploratory, multi-site, observational study evaluating the cytokinome profile in patients with her2 positive metastatic breast cancer candidate to receive Trastuzumab Emtansine. |
GIM21
(LiqERBcept) |
Liquid Biopsy: intercepting mutational trajectories of HER2 breast cancer in patients under T-DM1 treatment |
GIM22
(ERICA) |
Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study - ERICA trial |
GIM23
(POSTER) |
Prospective observational study of adjuvant hormone treatment in estrogen-receptor positive premenopausal early breast cancer patients |
GIM24
(PALBO-BP) |
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial - Palbo-BP |
GIM25
(CAPT) |
A Phase II trial of atezolizumab plus CArboplatin plus Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients |
GIM26
(TRASTHER) |
Observational study of effectiveness and safety of trastuzumab emtansine (T-DM1) |
GIM27
(THERAPY) |
Non-interventional, multicentric, prospective, observational study to describe the effectiveness of tucatinib in combination with capecitabine and trastuzumab in the treatment of metastatic HER-2 positive breast cancer patients in real world setting |
GIM28
(ELMER) |
EvoLution of Neoadjuvant TreatMent in 'triple-negative' or 'HER-2-positive' breast cancer diagnosed in the EaRly phase: retrospective multicentre study on the
therapeutic approach most commonly adopted in the Italian oncology centres |
GIM30
(RAPID) |
An observational, multicenter study evaluating the safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose combination: the RAPID study |
